For information on the latest Parkinson’s research please visit the European Parkinson’s Disease Association website.
Horse tranquilliser trial is awarded $750,000 grant for Parkinson’s research
News
Author: Simge Eva DoganPublished: 26 July 2018
Prep:
Cook:
Serves:
Researchers at the University of Arizona College of Medicine, Tucson, US, will be trialling ketamine – a recreational drug previously used to medicate people with depression – as a treatment for Parkinson’s.
The research – led by Dr Scott Sherman – is being supported with a three-year grant of $750,000 from the Arizona Biomedical Research Commission.
The initial clinical trial will test the effect of ketamine for treating dyskinesia in 10 patients. In addition, the researchers will carry out a separate rodent study to examine how the drug affects the brain.
Dr Scott Sherman, a neurologist at the University of Arizona College of Medicine, said: “Ketamine has been long overlooked. Now it could prove very useful for Parkinson’s patients.”
For more information on this article click here.
Last Month
Next Month
Share this story
Related articles
Special reports
Neurologists should be ‘guides not gods’ – Part 2
Top expert Bastiaan Bloem argues the case for a more holistic approach
READ MORE
Interviews
Swimming the English Channel for Parkinson’s
From England to France without a wetsuit
READ MORE
Advances
3 incredible walking inventions that Parkinson’s patients need to know about
Top tech: from laser-guided shoes to vibrating walking sticks
READ MORE
Comments